Advertisement
Advertisement
U.S. Markets open in 2 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

NeuroPace, Inc. (NPCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.2000+0.0300 (+0.95%)
At close: 04:00PM EDT
3.0400 -0.16 (-5.00%)
After hours: 04:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1700
Open3.2000
Bid0.0000 x 2200
Ask3.4100 x 1100
Day's Range3.2000 - 3.5200
52 Week Range3.1000 - 17.8000
Volume11,478
Avg. Volume30,979
Market Cap77.805M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.7460
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.17
  • GlobeNewswire

    NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

    MOUNTAIN VIEW, Calif. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management is scheduled to present on Tuesday, September 13 at 12:20 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors”

  • Motley Fool

    NeuroPace, Inc. (NPCE) Q2 2022 Earnings Call Transcript

    Joining me from NeuroPace are Mike Favet, CEO; and Rebecca Kuhn, CFO. Earlier today, NeuroPace released financial results for the second quarter ended June 30, 2022. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update

    MOUNTAIN VIEW, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending June 30, 2022. Recent Highlights Announced exclusive U.S. distribution agreement with DIXI Medical to sell its stereo EEG electrodes to Epilepsy Monitoring Units (EMUs)Completed sales team expansion initiativeBegins enrollment in the NAUTILUS s

Advertisement
Advertisement